Ferring ADAPT-1 Trial Builds on Dosing Evidence for Follitropin Delta
The ADAPT-1 trial was a multicentre, randomised, assessor-blind study involving 300 women aged 18-40 years undergoing IVF or ICSI. 3 The trial compared the efficacy and safety of follitropin delta and follitropin alfa using conventional dosing regimens with a primary endpoint of number of oocytes retrieved.
Currently, follitropin delta is approved for use via a dosing algorithm based on serum anti-Müllerian Hormone (AMH) and bodyweight individualised for each patient, and aims to obtain an ovarian response which is associated with a favourable safety/efficacy profile. The clinical value of this approach has been well established 4,5,6,7,8, particularly in treatment-naïve patients where the algorithm aims to achieve 8–14 retrieved oocytes while minimising the risk of ovarian hyperstimulation syndrome (OHSS) to optimise the live birth rate in a fresh and frozen transfer cycle. 4,5,6,7,8
Key Findings:
Ovarian Response: Both treatment groups achieved a mean of 9.9 oocytes retrieved, indicating similar efficacy
Clinical Pregnancy Rates: Clinical pregnancy rates were similar for follitropin delta 31.6% versus 31.0% for follitropin alfa
Drug Product Usage: After measurement unit conversion, the mean total dose patients were exposed to was numerically lower for follitropin delta (143.7±33.6 µg) than follitropin alfa (154.3±23.1 µg or 2,105±315 IU)
OHSS Rates: Early OHSS rates were low (2.5% for follitropin delta and 3.0% for follitropin alfa), with no cycle cancellations due to excessive ovarian response on either arm of the study.
Dr Andrea Bernabeu, Medical Director at Instituto Bernabeu and principal investigator of the ADAPT-1 trial, said: "No patients we see as fertility doctors are the same and the ability to optimise therapy based on patients age, treatment goal and whether they have a high or low response to follicular stimulation are all relevant. These data provide confidence and expand our understanding for dosing in follitropin delta."
Pierre-Yves Berclaz, Chief Science and Medical Officer at Ferring Pharmaceuticals, stated: "The ADAPT-1 trial results confirm the efficacy and safety of follitropin delta across the full range of dosing strategies, making it the only recombinant FSH with robust clinical evidence supporting multiple dosing strategies. Ferring will take forward the implications of this study in future dialogue with regulatory authorities."
About GnRH protocols
Gonadotrophin-releasing hormone (GnRH) agonists and antagonists are used as concomitant treatment during ovarian stimulation to prevent premature luteinisation and ovulation for IVF/ICSI. 7,8
About Follitropin Delta (Rekovelle ®)
Follitropin delta is a human cell line-derived rFSH with an approved dosing algorithm designed for a predictable ovarian response. 3 It is the first rFSH derived from a human cell line (PER.C6 ® cell line). Follitropin delta is structurally and biochemically distinct from other existing rFSH gonadotrophins. 3,4 Follitropin delta is approved in certain markets for use in controlled ovarian stimulation for the development of multiple follicles in women undergoing assisted reproductive technologies (ART), such as IVF or ICSI cycle. The individualised dosing of follitropin delta is determined using an approved algorithm, based on a woman's AMH level and body weight. 3,5 AMH is a biomarker used to assess ovarian reserve and can help predict ovarian response. 5,6 The follitropin delta dose should be based on AMH level, measured using the ELECSYS AMH Plus immunoassay from Roche, the ACCESS AMH Advanced from Beckman Coulter, or LUMIPULSE G AMH from Fujirebio. 3
About Ferring Pharmaceuticals
Ferring Pharmaceuticals is a privately owned, research-driven, specialty biopharmaceutical group committed to building families and helping people live better lives. We are leaders in reproductive medicine with a strong heritage in areas of gastroenterology and urology, and are at the forefront of innovation in uro-oncology gene therapy. Ferring was founded in 1950 and employs more than 7,000 people worldwide. The company is headquartered in Saint-Prex, Switzerland, and has operating subsidiaries in more than 50 countries which market its medicines in over 100 countries.
Learn more at www.ferring.com, or connect with us on LinkedIn, Instagram, YouTube, Facebook and X.
REFERENCES
1 – Arce JC, Larsson P, Garcia-Velasco JA; Establishing the follitropin delta dose that provides a comparable ovarian response to 150 IU/day follitropin alfa; RBMO; 2020
2 – Yang R, Zhang Y, Liang X et al; Comparative clinical outcome following individualized follitropin delta dosing in Chinese women undergoing ovarian stimulation for in vitro fertilization / intracytoplasmic sperm injection; Reproductive Biology and Endocrinology; 2022
3 – Clinical Trials.gov page: https://clinicaltrials.gov/study/NCT05263388 (Accessed June 2025)
4 – Andersen, A. N., Nelson, S. M., Fauser, B. et al. (2017). Individualized versus conventional ovarian stimulation for in vitro fertilization: A multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial. Fertility and Sterility, 107(2), 387-396.
5 – Bosch E, Havelock J, Martin FS, Rasmussen BB, Klein BM, Mannaerts B, Arce JC; ESTHER-2 Study Group. Follitropin delta in repeated ovarian stimulation for IVF: a controlled, assessor-blind Phase 3 safety trial. Reprod Biomed Online. 2019 Feb;38(2):195-205. PMID: 30594482.
6 – Ishihara O, Arce JC, Japanese Follitropin Delta Phase 3 Trial G. Individualized follitropin delta dosing reduces OHSS risk in Japanese IVF/ICSI patients: a randomized controlled trial. Reprod Biomed Online. 2021 May;42(5):909-18. PubMed PMID: 33722477. Epub 2021/03/17.
7 – Qiao J, Zhang Y, Liang X, et al. A randomised controlled trial to clinically validate follitropin delta in its individualised dosing regimen for ovarian stimulation in Asian IVF/ICSI patients. Hum Reprod. 2021 Jun 28;36(9):2452-62. PubMed PMID: 34179971. Epub 2021/06/29.
8 – Blockeel C, Griesinger G, Rago R, et al. Prospective multicenter non-interventional real-world study to assess the patterns of use, effectiveness and safety of follitropin delta in routine clinical practice (the PROFILE study). Frontiers in Endocrinology. 2022 Dec 22;13:992677. PMID: 36619578.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
2 hours ago
- Newsweek
Republican Unloads Medicaid-Related Stock Before Voting For Trump Tax Bill
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A Republican Congressman sold a Medicaid-related stock before voting for President Donald Trump's massive tax and spending package, which affects Medicaid. In May, Pennsylvania Representative Robert Bresnahan sold stocks in Centene Corporation, a healthcare company that works as an intermediary for government and private healthcare programs, while debates about the tax package, called the "One Big, Beautiful Bill," continued. The trade has recently been made publicly available. Newsweek contacted representatives for Bresnahan by email outside of business hours to comment on this story. Why It Matters The House of Representatives on Thursday passed the "One Big, Beautiful Bill" 218 votes to 214 after months of internal GOP divisions and last-minute negotiations. UNITED STATES - NOVEMBER 15: Rep.-elect Robert Bresnahan, R-Pa., poses for a photo on the House steps after freshman members of Congress posed for their class photo on the House steps of the Capitol on... UNITED STATES - NOVEMBER 15: Rep.-elect Robert Bresnahan, R-Pa., poses for a photo on the House steps after freshman members of Congress posed for their class photo on the House steps of the Capitol on Friday, November 15, 2024. More Bill Clark/CQ Roll Call via AP Images The legislation extends Trump's 2017 tax cuts, eliminates taxes on tips and overtime, and boosts funding for immigration enforcement and defense. The bill will also reduce Department of Health and Human Services budget by $880 billion over 10 years, which would include cuts to Medicaid alongside other measures such as implementing work requirements. The CBO estimates that the bill would result in 11.8 million people losing health insurance by 2034, with the majority of those people losing coverage from Medicaid. Meanwhile, members of Congress are allowed to buy and sell stocks, but the practice has attracted bipartisan criticism because of concerns it may facilitate insider trading, if lawmakers are privy to information about assets that could move markets. There are also concerns politicians with stock holdings can influence the assets they hold to inflate their share value. What To Know According to his financial disclosures, Bresnahan purchased between $1,001 and $15,000 in Centene Corporation on April 8. On May 15, he sold those stocks. This came a week before the legislation initially passed in the House. In July, it was reported that shares in the company fell almost 40 percent after the insurer predicted its 2025 revenues would be hit. The disclosures were first reported by data platform Quiver Quantitative, which claimed Bresnahan does not manage his own stock portfolio and plans to set up a blind trust. What People Are Saying Speaking to Newsweek, Veljko Fotak, a finance professor at the University at Buffalo in New York, said the trade "definitely is not appropriate." "It does suggest he thought the value of the shares would tank. His position allowed him to be a better judge of that probability than you or I. He did not have clear foresight—but he did have an unfair advantage, compared to other traders. "I will also say – the moral optics are made worse by the nature of the event. Profiting from inside information regarding the likelihood of legislation passing is ugly enough—when that inside information is about millions of individuals losing access to Medicare, the optics are somehow even worse.... This is Nero selling lumber while Rome is burning." On X, New Mexico Democrat Melanie Stansbury wrote: "This Congressman literally dumped stock in a Medicaid provider company right before this bill came to the Floor. Don't be fooled—these guys know exactly what they're doing." Elizabeth Warren, a Democratic Senator from Massachusetts, wrote: "Protecting his stock portfolio while ripping away health care from 17 million Americans This is Washington at its worst. We need to ban Congressional stock trading."
Business Upturn
4 hours ago
- Business Upturn
Shilpa Medicare subsidiary clears GMP inspection from ANVISA with no major observations
By Aman Shukla Published on July 4, 2025, 16:10 IST Shilpa Medicare Limited announced that its wholly owned subsidiary, Shilpa Pharma Lifesciences Limited (Unit-1), has successfully completed a Good Manufacturing Practice (GMP) inspection conducted by the Brazilian regulatory authority, ANVISA. In the exchange filing, the company shared, 'This is to inform you that the Shilpa Medicare Limited's 100% subsidiary, Shilpa Pharma Lifesciences Limited, Unit-1 has successfully completed GMP inspection from Brazilian regulatory authority, ANVISA. ' The inspection took place from June 30 to July 4, 2025, and concluded with no critical or major observations—a key milestone for the company's global regulatory compliance. Only minor procedural observations and recommendations were noted, which were discussed during the course of the audit. Shilpa Medicare stated that it remains committed to maintaining the highest quality and regulatory standards. The company will submit a Corrective and Preventive Action (CAPA) plan to address the minor points raised, within the stipulated timelines set by the agency. This successful outcome reinforces Shilpa's position in regulated markets and supports its ongoing efforts to expand its international presence, particularly in Latin America. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Washington Post
4 hours ago
- Washington Post
Why the GOP's Medicaid cuts are less than meets the eye
Criticism of the just-passed Republican budget bill has focused on its supposedly 'deep cuts' to Medicaid. House Minority Leader Hakeem Jeffries warned: 'Children will be hurt. Families will be hurt. Women will be hurt. Seniors will be hurt. Everyday Americans with disabilities will be hurt.' The Congressional Budget Office projects that in 2034, 11.8 million fewer Americans will have Medicaid coverage because of the bill — a figure that has been cited more than any other in Democratic rhetoric.
